Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to uncover real-world diabetic kidney disease care in underserved groups

NCT ID NCT07348718

Knowledge-focused Sponsor: Rubix LS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study follows 2000 adults with type 2 diabetes and diabetic kidney disease from underserved communities. Researchers collect health data from medical records and questionnaires over 24 months to understand how the disease progresses and what treatments are used in routine care. No new treatments are given; the goal is to gather information to guide future studies and improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults (≥18 years) with type 2 diabetes and chronic kidney disease consistent with diabetic kidney disease (e.g., reduced eGFR and/or elevated UACR) receiving routine clinical care at participating sites. Sites will primarily include safety-net systems, community hospitals, and FQHC-affiliated networks, with intentional enrollment strategies to ensure meaningful representation of underserved populations disproportionately affected by DKD. Longitudinal clinical data will be obtained from medical records, supplemented by participant questionnaires capturing patient-reported outcomes and social determinants of health.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥18 years at the time of enrollment Documented diagnosis of type 2 diabetes mellitus in the medical record Evidence of chronic kidney disease consistent with diabetic kidney disease (DKD), defined by one or more of the following, with evidence of chronicity (present for ≥3 months based on prior laboratory results, diagnosis codes, or clinician documentation): eGFR \<60 mL/min/1.73 m², and/or Urine albumin-to-creatinine ratio (UACR) ≥30 mg/g Receiving ongoing clinical care at a participating site with medical record data available for longitudinal follow-up Able and willing to provide written informed consent (and authorization for medical record review, as applicable) and to complete registry questionnaires Exclusion Criteria: End-stage kidney disease at baseline (maintenance dialysis) or history of kidney transplant Type 1 diabetes mellitus Known primary kidney disease not primarily attributable to diabetes that, in the investigator's judgment, is expected to drive kidney outcomes (e.g., polycystic kidney disease, active glomerulonephritis, lupus nephritis, vasculitis) Inability to provide informed consent or comply with registry procedures (e.g., no feasible longitudinal follow-up through the participating site)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease (DKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Albuminuria chronic renal failure syndrome diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic kidney disease (DKD)

Contacts and locations

Locations

  • Rubix LS

    Lawrence, Massachusetts, 01840, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.